EntryPoint Capital LLC Makes New Investment in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

EntryPoint Capital LLC purchased a new stake in Tandem Diabetes Care, Inc. (NASDAQ:TNDM) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 8,167 shares of the medical device company’s stock, valued at approximately $294,000.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Baillie Gifford & Co. increased its holdings in Tandem Diabetes Care by 235.7% during the 4th quarter. Baillie Gifford & Co. now owns 746,109 shares of the medical device company’s stock valued at $26,875,000 after acquiring an additional 523,843 shares in the last quarter. GW&K Investment Management LLC grew its position in shares of Tandem Diabetes Care by 18.0% in the fourth quarter. GW&K Investment Management LLC now owns 2,123,488 shares of the medical device company’s stock valued at $76,488,000 after purchasing an additional 323,674 shares during the last quarter. Bellevue Group AG increased its stake in shares of Tandem Diabetes Care by 19.9% during the 3rd quarter. Bellevue Group AG now owns 1,850,891 shares of the medical device company’s stock worth $78,496,000 after purchasing an additional 307,624 shares in the last quarter. Stephens Investment Management Group LLC raised its position in shares of Tandem Diabetes Care by 22.1% during the 4th quarter. Stephens Investment Management Group LLC now owns 1,555,809 shares of the medical device company’s stock worth $56,040,000 after purchasing an additional 281,327 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. raised its position in shares of Tandem Diabetes Care by 89.3% during the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 515,062 shares of the medical device company’s stock worth $18,553,000 after purchasing an additional 242,965 shares during the last quarter.

Insider Transactions at Tandem Diabetes Care

In other Tandem Diabetes Care news, COO Jean-Claude Kyrillos purchased 10,538 shares of Tandem Diabetes Care stock in a transaction on Friday, March 7th. The shares were purchased at an average cost of $18.12 per share, with a total value of $190,948.56. Following the completion of the transaction, the chief operating officer now directly owns 10,538 shares in the company, valued at approximately $190,948.56. This represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 2.20% of the company’s stock.

Tandem Diabetes Care Price Performance

TNDM stock opened at $19.81 on Friday. The company has a market cap of $1.32 billion, a PE ratio of -10.26 and a beta of 1.45. The company has a current ratio of 2.90, a quick ratio of 2.32 and a debt-to-equity ratio of 1.29. The stock has a 50-day moving average price of $28.40 and a two-hundred day moving average price of $33.25. Tandem Diabetes Care, Inc. has a 12-month low of $17.64 and a 12-month high of $53.69.

Wall Street Analyst Weigh In

A number of brokerages have commented on TNDM. Citigroup cut Tandem Diabetes Care from a “buy” rating to a “neutral” rating and lowered their target price for the company from $35.00 to $24.00 in a report on Tuesday, March 4th. The Goldman Sachs Group dropped their price objective on Tandem Diabetes Care from $42.00 to $24.00 and set a “neutral” rating for the company in a research report on Monday, March 3rd. Sanford C. Bernstein lowered shares of Tandem Diabetes Care from an “outperform” rating to a “market perform” rating and reduced their target price for the company from $35.00 to $25.00 in a report on Friday, February 28th. Royal Bank of Canada decreased their price target on shares of Tandem Diabetes Care from $65.00 to $55.00 and set an “outperform” rating on the stock in a research note on Thursday, February 27th. Finally, Canaccord Genuity Group reissued a “buy” rating and issued a $63.00 price objective on shares of Tandem Diabetes Care in a research report on Wednesday, February 26th. Eight investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $45.38.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.